

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend the claims as follows:

Claims 1-11 (Canceled)

12. (Original) Monoclonal antibody as deposited under DSM ACC 2457.

13. (Currently Amended) A method for identifying a cancer cell comprising:

(a) providing a tissue biopsy sample; and

(b) determining the level of expression in said sample of the protein

consisting of the amino acid sequence **(SEQ ID NO: 2)**:

MAAAEGPVG DGELWQ TWLPNHV VFLRLRE GLKNQSP TEAEKP ASSSLP SSPPPQ LLTRNV VFGLGGEL
FLWDGED SSFLV VRLRGPS GGGEEP ALSQYQR LLCINP PLFEIY QVLLSPT QHHVAL IGIKGL MVLELPK
RWGKNSE FEGGKST VNCSTTP VAERFFT SSTSLTK HAAWYP SEILD PHVVLLT SDNVIRI YSLREPQ TP
TNVILSE AEEESL VLNKGR AYTA SLGETA VAFDFG PLDAVP KTLFGQ NGKDEV VAYPLY ILYENGET F
LTYISLL HSPGNI WKAVGS IAHASAA EDNYGYD ACAVLCL PCVPN ILVIAT ESGMLY HCVVLE GEEDDD
HTSEKSW DSRIDL IPSLYV FECVELE LALKLAS GEDDPF DSDSFSC PVKLHR DPKCPS RYHCTHE AGVHS
VGLTWI HKLHKFL GSDEED KDSLQEL STEQKCF VEHILCT RPLPCR QPAPIR GFWIVPD ILGPTMI CITST
YECLIW PLLSTV HPASP PLLCTRED VEVAE SSLRVLA ETPDS FEKHRS ILQRSV ANPAFL KASEKD IAPP
PEECLQL SRATQV FREQYIL KQDLAKE EIQR RVKLLCD QKKKQLED LSYCRE ERKSLRE MAERLAD K
YEEAKE KQEDIM NRMKK LLHSFHS ELPVLS DSDSER DMKKEL QLPDQL RHLGNA IKQVTM KKDYYQQK
MEKVLSP KPPTIIL SAYQRK CIQSIL KEEGEHIRE MVKQIND IRNHVNF,

wherein a sample comprising said protein at a level of expression that is greater than non-cancer cells indicates that said sample comprises a cancer cell.

14. (Previously Presented) The method according to claim 13, wherein said cancer cell is a cell in an epithelial or mesenchymal tumor.

15. (Previously Presented) The method according to claim 13, wherein said tissue

biopsy sample is from a mammal.

16. (Previously Presented) The method according to claim 15, wherein said mammal is a human.

17. (Previously Presented) The method of claim 13, wherein the step of determining the level of expression of said protein consisting of said amino acid sequence comprises binding an antibody to said protein.

18. (Previously Presented) The method of claim 13, wherein the step of determining the level of expression of said protein consisting of said amino acid sequence comprises annealing of a nucleic acid binding molecule specifically to a nucleic acid transcript encoding said protein.

19. (Previously Presented) The method of claim 17, wherein said antibody is a monoclonal antibody directed against said protein.

21. (Previously Presented) The method of claim 17, wherein said antibody is a chimeric protein.

23. (Currently Amended) A diagnostic kit comprising a protein binding molecule, wherein the protein binding molecule binds to the protein consisting of the amino acid sequence **(SEQ ID NO: 2)**:

MAAAEGPVGDELWQTWLPNHVFLRLREGLKNQSPTEAEKPASSSLPSSPPPQLLTRNVVFGLGGEL
FLWDGEDSSFLVVRLRGPGSGGEEPALSQYQRLLCINPPLFEIYQVLLSPTQHHVALIGIKGLMVLELPK
RWGKNSEFEGGKSTVNCSTTPVAERFFTSSTSLTLKHAAWYPSEILDPHVLLTSDNVIRIYSLREPQTP
TNVILSEAEESLVLNKGRA Y TASLGETAVAFDFGPLDAVPKTLFGQNGKDEVVAYPLYILYENGETFL
TYISLLHSPGNIWKAVGSIAHASAAEDNYGYDACAVLCPCVPNILVIATESGMLYHCVVLEGEEDDH
TSEKSWDSRIDLIPSLYVFECVELELALKLASGEDDPFDSDFSCPVKLHRDPKCPSRYHCTHEAGVHSVG
LTWIHKLHKFLGSDEEDKDSLQELSTEQKCFVEHILCTRPLPCRQPAPIRGFWIVPDILGPTMICITSTYEC
LIWPLLSTVHPASPPLLCTREDVEVAESSLRVLAETPDSFEKHRSILQRSVANPAFLKASEKDIAPPPEEC
LQLSRATQVFREQYILKQDLAKEEIQRRVKLLCDQKKKQLEDLSYCREERKSLREMAERLADKYEEA
KEKQEDIMNRMKKLLHSFHSSELPVLSDSERDMKKELQLIPDQLRHLGNAIKQVTMKKDYQQQKMEKV
LSLPKPTIILSAYQRKCIQSILKEEGEHIREMVKQINDIRNHVNF.

24. (Currently amended) A diagnostic kit comprising a nucleic acid, wherein the nucleic acid anneals specifically to a nucleic acid transcript that encodes the protein consisting of the amino acid sequence **(SEQ ID NO: 2)**:

MAAAEGPVG DGELWQTWLPNHVVFRLRLREGLKNQSPTEAEKPASSSLPSSPPPQLLTRNVVFGLGGEL
FLWDGEDSSFLVVR LRGPSSGGGEEPALSQYQRLLCINPPLFEIYQVLLSPTQHHVALIGIKGLMVLELPK
RWGKNSEFEGGKSTVNCSTTPVAERFFTSSTSLTLKHAAWYPSEILDPHVLLTSDNVIRIYSLREPQTP
TNVILSEAEESLVLNKG RAYTASLGETAVAFDFGPLDAVPKTLFGQNGKDEVVAYPLYILYENGETFL
TYISLLHSPGNIWKAVGSI AHASAAEDNYGYDACAVLCLPCVPNILVIATESGMLYHCVVLEGEEDDH
TSEKSWDSRIDLIPSLYVFECVELELALKLASGEDDPFDSDFSCPVKLHRDPKPSRYHCTHEAGVHSVG
LTWIIHKLHKFLGSDEEDKDSLQELSTEQKCFVEHILCTRPLPCRQPAPIRGFWIVPDILGPTMICITSTYEC
LIWPLLSTVHPASPPLLCTREDVEVAESSLRVLAETPDSFEKHRSILQRSVANPAFLKASEKDIAPPPEEC
LQLLSRATQVFREQYILKQDLAKEEIQRRVKLLCDQKKKQLEDLSYCREERKSLREMAERLADKYEEA
KEKQEDIMNRMKKLLHSFHS ELPVLSDSERDMKKELQLIPDQLRHLGNAIKQVTMCKDYQQQKMEKV
LSLPKPTIILSAYQRKCIQSILKEEGEHIREMVKQINDIRNHVNF.

25. (Previously Presented) The kit of claim 23 further comprising in whole or in part, the protein consisting of said amino acid sequence, for use as a control sample.

26. (Previously Presented) The kit of claim 24 further comprising in whole or in part, the protein consisting of said amino acid sequence, for use as a control sample.

27. (Cancelled)

28. (Cancelled)

29. (Previously Presented) The method of claim 17, wherein said antibody is a natural antibody, a recombinant antibody or a chimeric protein.